Please assess the completion status of the following clinical trial:

Trial Title: Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients, 3-7 years 11 months of age.~2. Each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent. Each patient must also give assent to study participation.~3. Patients must have a diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) bipolar disorder and must currently display an acute manic, hypomanic or mixed episode as determined by DSM-IV criteria. This includes the following diagnoses: 296.4x, Bipolar I Disorder, Most Recent Episode Manic; 296.6x, Bipolar I Disorder, Most recent Episode Mixed; and 296.0x, Bipolar I Disorder, Single Manic Episode, Bipolar II Disorder, Most Recent Episode Hypomanic.~4. Patients must have an initial score (at day 0) on the YMRS total score of at least 20.~5. Subjects and their caretakers should be fluent in English.~Exclusion Criteria:~1. Clinically significant or unstable hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, hematologic or other systemic medical conditions.~2. Neurologic disorders including epilepsy, stroke, or severe head trauma.~3. Clinically significant laboratory abnormalities, on any of the following tests: CBC with differential, electrolytes, BUN, creatinine, hepatic transaminases, urinalysis, thyroid indices (T3, Total T4, Free T4, TSH), and EKG.~4. Mania due to a general medical condition or substance-induced mania (DSM-IV).~5. Mental retardation (IQ \<70), evidence of Fetal Alcohol Syndrome or an Alcohol-Related Neurodevelopmental Disorder.~6. History of hypersensitivity to or intolerance of risperidone or valproate.~7. Prior history of risperidone or valproate non-response.~8. Judged clinically to be at serious suicidal risk.~9. Participation in a clinical trial of another investigational drug within 1 month (30 days) prior to study entry.~10. Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections and day 0.~    -

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Valproate (VPA) (Type: ACTIVE_COMPARATOR): VPA was administered in liquid form, matched for taste and color with the placebo. Medication was administered in a double-blinded manner on a twice-daily basis. Patients randomized to VPA were administered an initial dose of 10 mg/kg/day on a twice daily schedule beginning on day 0. VPA levels were adjusted to achieve a blood level of 80-100 lg/mL. An independent, unblinded study psychiatrist adjusted VPA doses to achieve a therapeutic level
- Risperidone (Type: ACTIVE_COMPARATOR): Risperidone was administered in liquid form matched for taste and color to the placebo. Medications were administered in a double-blinded manner on a twice-daily basis.
- Placebo (Type: PLACEBO_COMPARATOR): The placebo was administered in liquid form, matched for taste and color with the active comparator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete